A novel treatment for refractory primary biliary cirrhosis?

S. Miyaguchi, H. Ebinuma, H. Imaeda, Y. Nitta, T. Watanabe, Hidetsugu Saito, H. Ishii

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.

Original languageEnglish
Pages (from-to)1518-1521
Number of pages4
JournalHepato-Gastroenterology
Volume47
Issue number36
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Bezafibrate
Biliary Liver Cirrhosis
Guanosine Triphosphate
Ursodeoxycholic Acid
Hyperlipidemias
Therapeutics
Enzymes
Immunoglobulin M
Reference Values
Immunoglobulin G
Liver

Keywords

  • Bezafibrate
  • PBC

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Miyaguchi, S., Ebinuma, H., Imaeda, H., Nitta, Y., Watanabe, T., Saito, H., & Ishii, H. (2000). A novel treatment for refractory primary biliary cirrhosis? Hepato-Gastroenterology, 47(36), 1518-1521.

A novel treatment for refractory primary biliary cirrhosis? / Miyaguchi, S.; Ebinuma, H.; Imaeda, H.; Nitta, Y.; Watanabe, T.; Saito, Hidetsugu; Ishii, H.

In: Hepato-Gastroenterology, Vol. 47, No. 36, 2000, p. 1518-1521.

Research output: Contribution to journalArticle

Miyaguchi, S, Ebinuma, H, Imaeda, H, Nitta, Y, Watanabe, T, Saito, H & Ishii, H 2000, 'A novel treatment for refractory primary biliary cirrhosis?', Hepato-Gastroenterology, vol. 47, no. 36, pp. 1518-1521.
Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H et al. A novel treatment for refractory primary biliary cirrhosis? Hepato-Gastroenterology. 2000;47(36):1518-1521.
Miyaguchi, S. ; Ebinuma, H. ; Imaeda, H. ; Nitta, Y. ; Watanabe, T. ; Saito, Hidetsugu ; Ishii, H. / A novel treatment for refractory primary biliary cirrhosis?. In: Hepato-Gastroenterology. 2000 ; Vol. 47, No. 36. pp. 1518-1521.
@article{dd14ba8794da458f932e0964dd04ed2f,
title = "A novel treatment for refractory primary biliary cirrhosis?",
abstract = "Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.",
keywords = "Bezafibrate, PBC",
author = "S. Miyaguchi and H. Ebinuma and H. Imaeda and Y. Nitta and T. Watanabe and Hidetsugu Saito and H. Ishii",
year = "2000",
language = "English",
volume = "47",
pages = "1518--1521",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "36",

}

TY - JOUR

T1 - A novel treatment for refractory primary biliary cirrhosis?

AU - Miyaguchi, S.

AU - Ebinuma, H.

AU - Imaeda, H.

AU - Nitta, Y.

AU - Watanabe, T.

AU - Saito, Hidetsugu

AU - Ishii, H.

PY - 2000

Y1 - 2000

N2 - Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.

AB - Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.

KW - Bezafibrate

KW - PBC

UR - http://www.scopus.com/inward/record.url?scp=0033636090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033636090&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 1518

EP - 1521

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 36

ER -